Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitisClin Transl Sci. 2024; 17:e13908 Eriksson J, Chenel M, Sjögren E.Infectious diseasesJournalPBPK/PBBMPharmetheus Affiliates Senior Director, MIDD ConsultantJohanna ErikssonSee bio Chief Research OfficerMarylore ChenelSee bio Principal Director, PBPK & PBBM Scientific LeadErik SjögrenSee bio